MLSS

Business Context and Reporting Period

Company: Milestone Scientific Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Milestone Scientific develops and markets the STA System, a computer-controlled local anesthesia delivery device for the dental industry, and is pursuing medical applications for its CompuFlo pressure force technology. The company operates as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net product sales increased by 16.2% ($357,759) compared to Q1 2009. This was driven primarily by a 117.2% increase in international handpiece sales, largely due to shipments to China.
• Profitability Turnaround: The company reported a net income of $83,922 in Q1 2010, a significant improvement from a net loss of $561,642 in the same period in 2009. Operating income turned positive ($31,700) from a loss of $508,168.
• Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by 10.8% ($187,113), primarily due to reduced marketing expenses ($284,000 decrease) and lower sales salaries ($114,000 decrease).
• Cash Flow: Operating cash flow turned positive ($248,437) from negative ($200,257) in the prior year, aided by a decrease in accounts receivable and an increase in accounts payable.
• Inventory and Advances: Current assets increased significantly due to a buildup of inventory and advances to contract manufacturers ($595,978 increase) to fulfill a 12,000-unit purchase order for the Chinese market.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: The filing explicitly states that the company's historical losses raise "substantial doubt about its ability to continue as a going concern." Management notes that if positive operating cash flows cannot be sustained or additional capital cannot be raised, the company may be forced to curtail development or reduce marketing.
• Strategic Focus: Management is focused on increasing global penetration of the STA System and pursuing strategic collaborations for medical applications of CompuFlo technology. A joint venture agreement with Chinese partners for orthopedic and epidural drug delivery is in progress but not finalized as of March 31, 2010.
• Unusual Items: Net income included $61,916 of "Other Income" from the sale of tax credits under the New Jersey Technology Business Tax Certificate Program.
• Customer Concentration: Three customers accounted for approximately 63% of revenue in Q1 2010. One major customer (a China-based distributor) accounted for 19% of revenue in the prior year.
• Debt Obligations: The company has a $450,000 note payable to a shareholder due June 30, 2012, with a 12% interest rate. Accrued interest on various notes totaled approximately $230,000 as of March 31, 2010.

Investor Verification Checklist

• Cash Runway: Verify if the current cash balance ($1.2M) and positive operating cash flow are sufficient to fund operations without immediate dilution or new debt, given the "going concern" warning.
• China Order Fulfillment: Confirm the status of the 12,000-unit STA System order for the Chinese distributor and the associated advances to contract manufacturers ($637,558 recorded in Q1).
• Debt Service: Review the terms of the $450,000 shareholder note and the accrued interest obligations to assess near-term liquidity pressure.
• Revenue Sustainability: Assess whether the revenue growth is sustainable given the heavy reliance on three major distributors and the specific nature of the China order.
• Joint Venture Progress: Monitor the finalization of the joint venture agreement with China National Medicines Corporation and Yichang Humanwell Pharmaceutical Co. Ltd. for medical applications.